BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 17189388)

  • 21. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
    Daly JM; Jannot CB; Beerli RR; Graus-Porta D; Maurer FG; Hynes NE
    Cancer Res; 1997 Sep; 57(17):3804-11. PubMed ID: 9288791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
    Lim SJ; Lopez-Berestein G; Hung MC; Lupu R; Tari AM
    Oncogene; 2000 Dec; 19(54):6271-6. PubMed ID: 11175341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
    Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
    Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
    Shimizu H; Seiki T; Asada M; Yoshimatsu K; Koyama N
    Oncogene; 2003 Feb; 22(6):831-9. PubMed ID: 12584562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
    Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.
    Brandt R; Wong AM; Hynes NE
    Oncogene; 2001 Sep; 20(39):5459-65. PubMed ID: 11571643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
    Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways.
    Rivas MA; Carnevale RP; Proietti CJ; Rosemblit C; Beguelin W; Salatino M; Charreau EH; Frahm I; Sapia S; Brouckaert P; Elizalde PV; Schillaci R
    Exp Cell Res; 2008 Feb; 314(3):509-29. PubMed ID: 18061162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emergence of ErbB2 expression in cultured rat hepatocytes correlates with enhanced and diversified EGF-mediated signaling.
    Scheving LA; Zhang L; Stevenson MC; Kwak ES; Russell WE
    Am J Physiol Gastrointest Liver Physiol; 2006 Jul; 291(1):G16-25. PubMed ID: 16769812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin.
    Vasilcanu R; Vasilcanu D; Sehat B; Yin S; Girnita A; Axelson M; Girnita L
    Mol Pharmacol; 2008 Mar; 73(3):930-9. PubMed ID: 18070930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
    Marx C; Yau C; Banwait S; Zhou Y; Scott GK; Hann B; Park JW; Benz CC
    Mol Pharmacol; 2007 Jun; 71(6):1525-34. PubMed ID: 17392524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. delta-Opioid receptor-stimulated Akt signaling in neuroblastoma x glioma (NG108-15) hybrid cells involves receptor tyrosine kinase-mediated PI3K activation.
    Heiss A; Ammer H; Eisinger DA
    Exp Cell Res; 2009 Jul; 315(12):2115-25. PubMed ID: 19362548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W; Gerard CM; Liu L; Baudson NM; Ory TL; Spector NL
    Oncogene; 2005 Sep; 24(41):6213-21. PubMed ID: 16091755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions.
    Spangenberg C; Lausch EU; Trost TM; Prawitt D; May A; Keppler R; Fees SA; Reutzel D; Bell C; Schmitt S; Schiffer IB; Weber A; Brenner W; Hermes M; Sahin U; Türeci O; Koelbl H; Hengstler JG; Zabel BU
    Cancer Res; 2006 Apr; 66(7):3715-25. PubMed ID: 16585198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.
    Grunt TW; Wagner R; Grusch M; Berger W; Singer CF; Marian B; Zielinski CC; Lupu R
    Biochem Biophys Res Commun; 2009 Jul; 385(3):454-9. PubMed ID: 19467222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Copine-III interacts with ErbB2 and promotes tumor cell migration.
    Heinrich C; Keller C; Boulay A; Vecchi M; Bianchi M; Sack R; Lienhard S; Duss S; Hofsteenge J; Hynes NE
    Oncogene; 2010 Mar; 29(11):1598-610. PubMed ID: 20010870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.